Chen C, Guo DH, Cao X, et al. Risk factors for thrombocytopenia in adult Chinese patients receiving linezolid therapy. Curr Ther Res Clin Exp. 2012;73(6):195–206. https://doi.org/10.1016/j.curtheres.2012.07.002.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dong HY, Xie J, Chen LH, et al. Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients. Eur J Clin Microbiol Infect Dis. 2014;33(6):1029–35. https://doi.org/10.1007/s10096-013-2041-3.

Article  CAS  PubMed  Google Scholar 

Lin YH, Wu VC, Tsai IJ, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents. 2006;28(4):345–51. https://doi.org/10.1016/j.ijantimicag.2006.04.017.

Article  CAS  PubMed  Google Scholar 

González-Del Castillo J, Candel FJ, Manzano-Lorenzo R, et al. Predictive score of haematological toxicity in patients treated with linezolid. Eur J Clin Microbiol Infect Dis. 2017;36(8):1511–7. https://doi.org/10.1007/s10096-017-2960-5.

Article  CAS  PubMed  Google Scholar 

Hsu YC, Chen SY, Hung YJ, et al. Renal replacement therapy and concurrent fluconazole therapy increase linezolid-related thrombocytopenia among adult patients. Sci Rep. 2022;12(1):9894. https://doi.org/10.1038/s41598-022-13874-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Inoue Y, Takekuma Y, Miyai T, et al. Use of Japanese big data from electronic medical records to investigate risk factors and identify their high-risk combinations for linezolid-induced thrombocytopenia. Eur J Clin Pharmacol. 2023;79(3):415–25. https://doi.org/10.1007/s00228-023-03455-x.

Article  CAS  PubMed  Google Scholar 

Nukui Y, Hatakeyama S, Okamoto K, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother. 2013;68(9):2128–33. https://doi.org/10.1093/jac/dkt133.

Article  CAS  PubMed  Google Scholar 

Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006;42(1):66–72. https://doi.org/10.1086/498509.

Article  PubMed  Google Scholar 

Pea F, Viale P, Cojutti P, et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012;67(8):2034–42. https://doi.org/10.1093/jac/dks153.

Article  CAS  PubMed  Google Scholar 

Lin B, Hu Y, Xu P, et al. Expert consensus statement on therapeutic drug monitoring and individualization of linezolid. Front Public Health. 2022;10:967311. https://doi.org/10.3389/fpubh.2022.967311.

Article  PubMed  PubMed Central  Google Scholar 

Matsumoto K, Shigemi A, Takeshita A, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents. 2014;44(3):242–7. https://doi.org/10.1016/j.ijantimicag.2014.05.010.

Article  CAS  PubMed  Google Scholar 

Kawasuji H, Tsuji Y, Ogami C, et al. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients. BMC Pharmacol Toxicol. 2021;22(1):13. https://doi.org/10.1186/s40360-021-00479-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cattaneo D, Orlando G, Cozzi V, et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents. 2013;41(6):586–9. https://doi.org/10.1016/j.ijantimicag.2013.02.020.

Article  CAS  PubMed  Google Scholar 

Takahashi Y, Takesue Y, Nakajima K, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother. 2011;17(3):382–7. https://doi.org/10.1007/s10156-010-0182-1.

Article  CAS  PubMed  Google Scholar 

Hanai Y, Matsuo K, Ogawa M, et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J Infect Chemother. 2016;22(8):536–42. https://doi.org/10.1016/j.jiac.2016.05.003.

Article  PubMed  Google Scholar 

Tanaka R, Suzuki Y, Morinaga Y, et al. A retrospective test for a possible relationship between linezolid-induced thrombocytopenia and hyponatraemia. J Clin Pharm Ther. 2021;46(2):343–51. https://doi.org/10.1111/jcpt.13287.

Article  CAS  PubMed  Google Scholar 

Ichie T, Suzuki D, Yasui K, et al. The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis. J Clin Pharm Ther. 2015;40(3):279–84. https://doi.org/10.1111/jcpt.12260.

Article  CAS  PubMed  Google Scholar 

Natsumoto B, Yokota K, Omata F, et al. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection. 2014;42(6):1007–12. https://doi.org/10.1007/s15010-014-0674-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Onita T, Ishihara N, Ikebuchi A, et al. Pharmacokinetic and pharmacodynamic simulation for the quantitative risk assessment of linezolid-associated thrombocytopenia. J Clin Pharm Ther. 2022;47(12):2041–8. https://doi.org/10.1111/jcpt.13747.

Article  CAS  PubMed  Google Scholar 

Zhang D, Xu Y, Wang X, et al. Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2023;79(10):1303–14. https://doi.org/10.1007/s00228-023-03542-z.

Article  CAS  PubMed  Google Scholar 

Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92. https://doi.org/10.1053/j.ajkd.2008.12.034.

Article  CAS  PubMed  Google Scholar 

SWOG. Cancer Research Network – Cancer Research and Biostatistics. https://stattools.crab.org/Calculators/twoArmNormal.htm, Accessed 26.08.2024.

Echeverría-Esnal D, Retamero A, Pardos SL, et al. Severe thrombocytopenia caused by linezolid poisoning in an underweight critically ill patient with renal impairment treated with the recommended doses. Enferm Infecc Microbiol Clin. 2016;34(3):213–4. https://doi.org/10.1016/j.eimc.2015.06.012.

Article  PubMed  Google Scholar 

Wang MG, Wang D, He JQ. Reversible recurrent profound thrombocytopenia due to linezolid in a patient with multi-drug resistant tuberculosis: a case report. Med (Baltim). 2018;97(34):e11997. https://doi.org/10.1097/MD.0000000000011997.

Article  Google Scholar 

Xiao B, Deng P, Jin H, et al. Lactic acidosis and Thrombocytopenia Associated with Linezolid Therapy: a Case Report. Am J Case Rep. 2018;19:1117–20. https://doi.org/10.12659/AJCR.911362.

Article  PubMed  PubMed Central  Google Scholar 

Hirano R, Sakamoto Y, Tachibana N, et al. Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients. Int J Clin Pharm. 2014;36(4):795–9. https://doi.org/10.1007/s11096-014-9961-6.

Article  CAS  PubMed  Google Scholar 

Rabon AD, Fisher JP, MacVane SH. Incidence and risk factors for development of Thrombocytopenia in patients treated with linezolid for 7 days or Greater. Ann Pharmacother. 2018;52(11):1162–4. https://doi.org/10.1177/1060028018783498.

Article  PubMed  Google Scholar 

Dai Y, Jiang S, Chen X, et al. Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients. J Clin Pharm Ther. 2021;46(3):807–13. https://doi.org/10.1111/jcpt.13359.

Article  CAS  PubMed  Google Scholar 

Shi C, Xia J, Ye J, et al. Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88(2):464–75. https://doi.org/10.1111/bcp.14965.